269
Participants
Start Date
December 26, 2017
Primary Completion Date
October 18, 2025
Study Completion Date
October 18, 2026
Tarlatamab
Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
Pembrolizumab
Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
CRS Mitigation Strategies
Participants will be treated with one of the CRS mitigation strategies.
Centre Hospitalier Universitaire Vaudois, Lausanne
Chris OBrien Lifehouse, Camperdown
Landeskrankenhaus Salzburg, Salzburg
Medizinische Universitaet Graz, Graz
Kantonsspital St Gallen, Sankt Gallen
Memorial Sloan Kettering Cancer Center, New York
Tri-Service General Hospital, Taipei
University of Pittsburgh Medical Center Cancer Pavillion, Pittsburgh
Fox Chase Cancer Center, Philadelphia
John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Winship Cancer Institute, Atlanta
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan District
Moffitt Cancer Center, Tampa
Sarah Cannon Research Institute, Nashville
The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic, Columbus
University Hospitals Cleveland Medical Center, Cleveland
Henry Ford Health System, Detroit
University of Chicago, Chicago
Ochsner Clinic Foundation, New Orleans
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
City of Hope National Medical Center, Duarte
Gustave Roussy, Villejuif
Universitaetsklinikum Wuerzburg, Würzburg
Yale New Haven Hospital, New Haven
Washington University, St Louis
Prince of Wales Hospital, Shatin, New Territories
National Cancer Center Hospital East, Kashiwa-shi
National Cancer Center Hospital, Chuo-ku
Wakayama Medical University Hospital, Wakayama
Nederlands Kanker Instituut Antoni van Leeuwenhoekziekenhuis, Amsterdam
Maastricht Universitair Medisch Centrum, Maastricht
Biokinetica SA, Józefów
Europejskie Centrum Zdrowia Otwock Szpital imienia Fryderyka Chopina, Otwock
Hospital Universitari Vall d Hebron, Barcelona
Hospital Clinic i Provincial de Barcelona, Barcelona
Christie Hospital, Manchester
Lead Sponsor
Amgen
INDUSTRY